Candida auris: Epidemiology and Antifungal Strategy
- PMID: 39656947
- PMCID: PMC11808652
- DOI: 10.1146/annurev-med-061523-021233
Candida auris: Epidemiology and Antifungal Strategy
Abstract
Candida auris is a recently emerged fungal pathogen that causes severe infections in healthcare settings around the globe. A feature that distinguishes C. auris from other fungal pathogens is its high capacity to colonize skin, leading to widespread outbreaks in healthcare facilities via patient-to-patient transmission. C. auris can persist on skin or in the surrounding environment for extended periods of time, and it exhibits greater antifungal resistance than other Candida species. These factors pose major obstacles for the prevention and treatment of C. auris infection. Recent reports have identified frequently colonized skin sites, risk factors for developing invasive infection, and patterns of antifungal resistance among C. auris strains, all of which help guide therapeutic options. In this review, we highlight key studies of C. auris epidemiology and antifungal resistance, discussing how these factors influence healthcare-associated transmission and treatment outcomes.
Keywords: Candida auris; antifungal; drug resistance; epidemiology; microbiome; skin colonization; transmission; treatment.
Figures
Similar articles
-
Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options.Microb Pathog. 2018 Dec;125:116-121. doi: 10.1016/j.micpath.2018.09.014. Epub 2018 Sep 8. Microb Pathog. 2018. PMID: 30205192 Review.
-
Candida auris: The recent emergence of a multidrug-resistant fungal pathogen.Med Mycol. 2019 Jan 1;57(1):1-12. doi: 10.1093/mmy/myy054. Med Mycol. 2019. PMID: 30085270 Review.
-
Candida auris: an Emerging Fungal Pathogen.J Clin Microbiol. 2018 Jan 24;56(2):e01588-17. doi: 10.1128/JCM.01588-17. Print 2018 Feb. J Clin Microbiol. 2018. PMID: 29167291 Free PMC article. Review.
-
The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England.J Med Microbiol. 2024 May;73(5):001820. doi: 10.1099/jmm.0.001820. J Med Microbiol. 2024. PMID: 38771623 Free PMC article. Review.
-
Candida auris in Greek healthcare facilities: Active surveillance results on first cases and outbreaks from eleven hospitals within Attica region.J Mycol Med. 2024 Jun;34(2):101477. doi: 10.1016/j.mycmed.2024.101477. Epub 2024 Mar 26. J Mycol Med. 2024. PMID: 38574412
Cited by
-
Diagnostic Approaches for Candida auris: A Comprehensive Review of Screening, Identification, and Susceptibility Testing.Microorganisms. 2025 Jun 24;13(7):1461. doi: 10.3390/microorganisms13071461. Microorganisms. 2025. PMID: 40731971 Free PMC article. Review.
-
Growth phase influences virulence in Candida auris systemic infection models.bioRxiv [Preprint]. 2025 Jun 2:2025.06.02.657403. doi: 10.1101/2025.06.02.657403. bioRxiv. 2025. PMID: 40501926 Free PMC article. Preprint.
-
Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.Front Microbiol. 2025 Jan 30;16:1554917. doi: 10.3389/fmicb.2025.1554917. eCollection 2025. Front Microbiol. 2025. PMID: 39949625 Free PMC article. Review.
-
Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida.J Fungi (Basel). 2025 Apr 1;11(4):271. doi: 10.3390/jof11040271. J Fungi (Basel). 2025. PMID: 40278091 Free PMC article. Review.
References
-
- Satoh K, Makimura K, Hasumi Y, et al. 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol 53:41–44 - PubMed
-
- Calvo B, Melo AS, Perozo-Mena A, et al. 2016. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J. Infect 73:369–74 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical